3,4,5-trimethoxystyrylarylaminopropenones as potential anticancer agents
US-9487482-B2 · Nov 8, 2016 · US
Inhibitors of the N-terminal domain of the androgen receptor
US11261152B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11261152-B2 |
| Application number | US-201816478914-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 19, 2018 |
| Priority date | Jan 20, 2017 |
| Publication date | Mar 1, 2022 |
| Grant date | Mar 1, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure provides compounds and methods for inhibiting or degrading the N-terminal domain of the androgen receptor, as well as methods for treating cancers such as prostate cancer.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound represented by formula VIIb: wherein: each R 8 is independently selected from halo, alkyl, or alkyloxy; each R 9 is independently selected from halo, alkyl, or alkyloxy; t is 0, 1, 2, 3, 4, or 5; and q is 0, 1, 2, 3, 4, or 5. 2. The compound of claim 1 , wherein each R 8 is independently selected from halo. 3. The compound of claim 1 , wherein each R 9 is independently selected from halo. 4. The compound of claim 1 , wherein t is 1, 2 or 3. 5. The compound of claim 1 , wherein q is 1, 2 or 3. 6. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable excipient. 7. A method of inhibiting an androgen receptor, comprising contacting the androgen receptor with the compound of claim 1 . 8. A method of inducing degradation of an androgen receptor, comprising contacting the androgen receptor with the compound of claim 1 . 9. A method of treating a mammal suffering from prostate cancer, comprising administering the compound of claim 1 to a mammal in need thereof.
Assignees
Inventors
Classifications
having one double bond between ring members or between a ring member and a non-ring member · CPC title
- C07C225/16Primary
and containing six-membered aromatic rings · CPC title
the carbon skeleton containing rings · CPC title
Polycyclic · CPC title
to an acyclic saturated chain · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11261152B2 cover?
- The present disclosure provides compounds and methods for inhibiting or degrading the N-terminal domain of the androgen receptor, as well as methods for treating cancers such as prostate cancer.
- Who is the assignee on this patent?
- Univ California, The Us Gov Represented By The Department Of Veterans Affairs, Us Gov Veterans Affairs
- What technology area does this patent fall under?
- Primary CPC classification C07C225/16. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).